SOURCE: Angle PLC

October 26, 2017 03:33 ET

Angle PLC: Total Voting Rights

GUILDFORD, SURREY--(Marketwired - Oct 26, 2017) - Angle PLC (OTCQX: ANPCY) (AIM: AGL)

AIM:AGL OTCQX:ANPCY

For immediate release 26 October 2017

ANGLE plc ("the Company")

Total Voting Rights

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, following the announcement of 12 October 2017, 7,481,570 New Ordinary Shares have been issued pursuant to the Further Subscription. Following completion of the Admission of the Further Subscription Shares, the total number of Ordinary Shares in issue is 82,297,344.

The figure of 82,297,344 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement entitled "Proposed Further Subscription For £2.8 Million" released on 12 October 2017 unless the context requires otherwise.

For further information ANGLE:

ANGLE plc   +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
   
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne
Corporate Broking - Alice Lane, Nikita Jain
  +44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee
  +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert
Kimberly Ha (US)
 
+44 (0) 203 727 1000
+1 212 850 5612

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.

ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/

The analysis of the cells that can be harvested from patient blood with ANGLE's ParsortixTM system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The ParsortixTM system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

As well as cancer, the ParsortixTM technology has the potential for deployment with several other important cell types in the future.

ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com

Contact Information